This page shows the latest BRVO news and features for those working in and with pharma, biotech and healthcare.
BRVO, one of the two main types of retinal vein occlusion, is caused by blood clots in a branch of the main vein in the retina, leading to blood and fluid ... If left untreated, BRVO can significantly impact a person's vision. Within the next three
Lilly says that, although 2011 and 2013 NICE guidance backs laser photocoagulation as a first-line treatment of visual impairment due to BRVO, clinical practice has since changed. ... NICE's next appraisal committee meeting on Eylea and its use in
macular oedema following branch retinal vein occlusion (BRVO), while more than 50% of patients in the Eylea arm gained at least three lines of vision. ... BRVO is a common cause of visual impairment in the elderly and is around three times more common
Bayer has also filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion (BRVO), a leading cause
retinal vein occlusion (BRVO), a common cause of visual impairment in the elderly. ... BRVO is around three times more common than CRVO so could provide a further fillip to growth momentum if approved.
Lucentis has a slightly expanded indication, which also covers branch retinal vein occlusion (BRVO), although only if treatment involving the use of lasers to seal blood vessels in the eye has
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...